Deproxen

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Deproxen

Quick Facts: Deproxen

Property Description
Active ingredient Naproxen Sodium
Form Tablet, Caplet, Oral Suspension
Pharmacological class Nonsteroidal Anti-Inflammatory Drug (NSAID)
Common use Relief of pain, inflammation, and fever
Origin Synthetic (Propionic acid derivative)

Deproxen's Identity and Pharmacological Class

Deproxen is a synthetic drug and a single-ingredient product classified as a Nonsteroidal Anti-Inflammatory Drug (NSAID), confirming its fundamental role as an anti-inflammatory agent and a non-opioid analgesic. The primary ingredient, Naproxen Sodium, is categorized as an NSAID and serves as an analgesic and antipyretic. It is chemically defined as a propionic acid derivative, sharing a common structural lineage with other established members of its therapeutic class. This classification ensures that the medicine achieves its effects through a well-understood peripheral mechanism of action, targeting biochemical processes rather than the central nervous system.


Composition and Available Drug Forms

The active ingredient in Deproxen is Naproxen Sodium, which is the sodium salt formulation of Naproxen, designed specifically to facilitate rapid absorption into the body following oral intake. This specific salt form is a key feature, as the sodium conjugation accelerates solubility, allowing for a quicker onset of action compared to Naproxen base formulations. The mechanism of action involves the inhibition of prostaglandin synthesis, which underlies its anti-inflammatory properties. Deproxen is primarily supplied in various common dosage forms, including the standard tablet and caplet, which may be available in both immediate-release and delayed-release (enteric-coated) versions.


General Purpose: Relief from Pain, Inflammation, and Fever

The general purpose of Deproxen is to provide concurrent relief from the three primary symptoms of distress: pain, inflammation, and fever. A typical use scenario is the temporary relief of aches and discomfort, such as those associated with muscular strain or mild seasonal fever. Its three distinct physiological actions are analgesic (pain-relieving), anti-inflammatory (reducing swelling and irritation), and antipyretic (reducing elevated body temperature). By effectively targeting these three simultaneous actions, the medication offers comprehensive relief from widespread physical discomfort and the body's generalized inflammatory response.

Regulatory References

  1. NIH DailyMed: Naproxen Sodium Label
  2. MedlinePlus Drug Information: Naproxen

What side effects are possible with Deproxen?

Possible side effects and safety information

The safety profile for Deproxen (Naproxen Sodium), classified as a Nonsteroidal Anti-Inflammatory Drug (NSAID), is documented through a formal framework of adverse reactions and systemic warnings, consistent with government regulatory information.

Adverse Reaction Scope

Category Description
Key adverse reaction categories Gastrointestinal disturbances, nervous system effects, skin reactions, and cardiovascular and renal risks.
Frequency classification Adverse reactions are classified by official tiers, including Common (e.g., headache, dyspepsia, nausea) and Rare (e.g., severe hepatic injury, anaphylactoid reactions, or gastrointestinal bleeding).
System-organ classes involved Gastrointestinal disorders are among the most frequently reported, alongside Nervous system disorders, Cardiovascular disorders, and Renal and urinary disorders.
Serious adverse reactions Officially documented serious risks include Gastrointestinal bleeding, ulceration, and perforation, as well as Cardiovascular thrombotic events such as myocardial infarction and stroke. Severe cutaneous adverse reactions (SCARs) are also listed.
Population-specific safety Older adults have a higher documented risk for serious gastrointestinal and renal adverse events. Patients with existing cardiovascular or renal conditions require particular attention, as specified in regulatory labels.
Duration-related patterns The official label states that the risk of serious Cardiovascular thrombotic events may increase with the duration of use, and such events may occur early in treatment.
Safety-related restrictions The medicine is contraindicated following coronary artery bypass graft (CABG) surgery and in individuals with a history of allergic-type reactions to aspirin or other NSAIDs.

Regulatory Safety Summary

The official safety information structures the understanding of risks by categorizing potential side effects based on frequency and affected system, thus providing a precise, non-advisory description of the medicine's limitations. The profile is further defined by explicit warnings regarding serious, life-threatening adverse reactions and definitive constraints on use related to pre-existing conditions.

Overdose and Emergency Response

Overdose and When to Seek Help

This section outlines the officially documented manifestations of Deproxen (Naproxen Sodium) overdose and the immediate emergency actions required, based strictly on government regulatory documents.

Documented Overdose Manifestations

Overdose often presents with symptoms affecting the gastrointestinal and nervous systems. Common signs listed in regulatory information include nausea, vomiting, epigastric distress, abdominal pain, drowsiness, dizziness, confusion, and tinnitus (ringing in the ears).

Severe Outcomes and Emergency Action

A massive overdose can lead to life-threatening outcomes, including gastrointestinal bleeding and perforation, acute kidney failure, seizures, and coma. Because there is no specific antidote, immediate intervention is critical.

Action Required (Regulator Mandate) Description (Label-Derived)
Immediate Help-Seeking Seek immediate medical attention or call a Poison Control Center right away in case of suspected overdose.
Life-Threatening Symptoms Contact emergency services at once if symptoms such as seizures or severe bleeding occur.

Supportive Management and Risk

Treatment primarily involves symptomatic and supportive treatment. Procedures like considering gastric lavage or administering activated charcoal may be used to limit absorption following recent, substantial ingestion. Regulatory documents note that elderly patients are at particularly high risk for severe adverse effects, specifically potentially fatal gastrointestinal complications.

Therapeutic Uses of Deproxen

What Deproxen Treats: Main Uses and Benefits

Deproxen is commonly used to provide symptomatic relief in conditions characterized by periods of heightened symptoms, and is used to manage symptoms related to physical discomfort, inflammatory states, and systemic imbalance. This medicine is relevant across domains where additional symptomatic support is needed, primarily for conditions involving inflammatory or irritative processes.

It is applied in addressing symptom clusters that may become intense or disruptive, such as the persistent joint pain and stiffness related to rheumatoid arthritis and osteoarthritis; the localized swelling of tendonitis and bursitis; and acute pain events like gouty arthritis flares and primary dysmenorrhea (menstrual cramps). This support contributes to easing the overall symptom load during periods of heightened symptoms, and may assist with maintaining comfort and easing functional strain.


Quick Fact: Therapeutic Support

Aspect of Use Primary Symptom Focus
Chronic Conditions Helps address symptoms of inflammatory joint diseases
Acute Pain Relevant when supportive symptom management is appropriate for sprains or strains
Episodic Relief Used for managing recurrent pain like menstrual cramps
Fever & Aches Contributes to easing general systemic discomfort

Regulatory References

  1. NIH MedlinePlus Drug Information on Naproxen

Eligibility and Restrictions for Use

Who Can and Cannot Use Deproxen?

The official eligibility profile for Deproxen (Naproxen Sodium) is defined by strict regulatory criteria, determining groups who may use the medicine and those for whom use is contraindicated or restricted.


Absolute Contraindications

Deproxen is formally contraindicated and must not be used by patients with a known hypersensitivity or history of allergic reactions (such as asthma or urticaria) to aspirin or other Nonsteroidal Anti-Inflammatory Drugs (NSAIDs). Absolute non-eligibility is defined for patients with severe heart failure, severe hepatic failure, or advanced renal disease. Use is also prohibited in the setting of peri-operative pain for Coronary Artery Bypass Graft (CABG) surgery and in patients with active gastrointestinal bleeding or ulcers.


Age and Life Stage Restrictions

Use is contraindicated during the third trimester of pregnancy and is restricted during the second trimester. Safety and efficacy are not established in children under two years of age; use is typically restricted to children aged ge 2 years for specific indications. Older adults are a restricted population requiring caution and the lowest effective dose due to increased risk of serious gastrointestinal events. Caution is also advised for patients with non-severe renal or hepatic impairment, which necessitates monitoring.

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section summarizes officially documented interactions for Deproxen (naproxen/naproxen sodium), strictly based on government regulatory labeling, and is not a substitute for medical advice.

Documented Interaction Categories

Category Implications
Pharmacodynamic Risk Enhancement Increased risk of gastrointestinal bleeding or ulceration when used with anticoagulants (e.g., Warfarin), anti-platelet agents, corticosteroids, and SSRIs/SNRIs. Concomitant use with other NSAIDs is generally avoided due to cumulative adverse effects.
Drug Clearance Modification May lead to elevated plasma concentrations and potential toxicity of drugs like Lithium and Methotrexate due to inhibition of their renal elimination. Probenecid can also increase Deproxen levels.
Efficacy Reduction May diminish the therapeutic effects of antihypertensives (ACE inhibitors, ARBs) and certain diuretics (furosemide, thiazides).

Specific Restrictions and Context

  • Contraindicated Combinations: Deproxen use is contraindicated in the peri-operative setting of Coronary Artery Bypass Graft (CABG) surgery.
  • Timing Requirement: Use is restricted for 8 to 12 days following the administration of Mifepristone.
  • Population Note: Increased risk of kidney function decline is noted when used with ACE Inhibitors/ARBs in elderly or volume-depleted patients.
  • Food/Substance: The official label mentions interactions with alcohol (increased bleeding risk) and potential delayed absorption due to antacids and sucralfate.

Mechanism of Action

The mechanism of action for Deproxen is defined by its targeted influence on the body's eicosanoid system, resulting in predictable physiological adjustments.

The drug's primary action involves the reversible, non-selective inhibition of Cyclooxygenase-1 (COX-1) and Cyclooxygenase-2 (COX-2). By binding to the active sites of these enzymes, the drug blocks the first molecular step in the conversion of arachidonic acid into prostanoid mediators. This mechanism results in a reduction of signaling within the inflammatory cascade.

The resulting reduction in prostaglandin synthesis in peripheral tissues reduces the sensitization of nociceptors to pain mediators and attenuates localized vascular changes. The mechanism also extends to the central nervous system where it reduces PGE2 synthesis in the hypothalamus, causing an alteration of the elevated thermoregulatory set-point. Furthermore, the sodium salt formulation accelerates the drug's absorption, resulting in a faster attainment of concentrations required for COX enzyme inhibition.

Dosage and Administration Information

How to Use Deproxen: Official Administration Guidelines

Deproxen (Naproxen/Naproxen Sodium) is authorized for oral administration only. Official usage instructions define specific dosing schedules based on the duration and nature of the condition, adhering to the principle of utilizing the lowest effective dose for the shortest duration necessary.


Administration and Dosage Principles

Instruction Detail
Route of Administration Strictly Oral (by mouth).
Intake Timing Must be taken with or immediately after food or swallowed with a full glass of water or milk to help manage gastrointestinal tolerance.
Dosing Frequency For chronic conditions, maintenance is typically twice daily (every 12 hours). For acute pain, the initial dose is often followed by a lower dose every 6 to 8 hours.
Dose Ranges Maintenance doses for chronic use typically range from 500 mg to 1,000 mg per day, with a temporary maximum limit of 1,500 mg per day for limited periods.

Form-Specific and Population Rules

Specific handling rules apply to different formulations. Delayed-release (enteric-coated) tablets must not be crushed, split, or chewed to preserve the intended site and timing of absorption. If the oral suspension is used, it must be shaken gently before use, and accurate measurement requires a calibrated device.

Standard guidelines suggest caution when administering Deproxen to older adults and recommend that a reduced daily dosage be considered in this population. Furthermore, use is generally advised against in patients with moderate to severe renal impairment.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Deproxen


Evidence for Chronic Inflammatory Joint Conditions

Deproxen was studied in numerous controlled clinical trials and subsequent long-term observational studies exploring symptom patterns in chronic conditions such as rheumatoid arthritis and osteoarthritis. This research examined how outcomes related to physical discomfort and daily functioning or activity level change over time in the observed populations. Specifically, studies monitored measures of joint pain intensity, stiffness, and patient-reported ability to perform daily activities over defined time intervals.

Reports from long-term, established use described repeated measurements of pain and stiffness symptoms in the studied populations. The research provides limited data exploring the medicine's influence on the structural progression of the joint disease itself. Instead, the evidence primarily focuses on symptom measurement.


Evidence for Acute Pain and Episodic Symptom Relief

Research examining Deproxen's use during conditions associated with acute or disruptive episodes, such as postoperative pain and primary dysmenorrhea (menstrual cramps), is primarily built upon randomized, double-blind, placebo-controlled clinical trials (RCTs) and meta-analyses. These studies were applied in research contexts involving fluctuating or unstable symptoms and often used a single-dose study design.

Researchers examined outcomes describing episodic or acute changes in pain, including the measured change in pain intensity and duration and the time to the use of additional pain medication. Findings across these short-term studies contribute to the broader evidence landscape by recording short-term changes in measured pain intensity and duration. The follow-up durations were limited in many of these studies, typically ranging from a single dose assessed over several hours up to a maximum of one week for acute flares.


What Research Gaps and Uncertainties Remain

The research highlights areas where certainty remains low or where data are still emerging. The evidence quality varies across studies, and the sample sizes were modest in some of the older trials. A key limitation is that comparative evidence is lacking for direct comparisons of Deproxen against all currently available pain and anti-inflammatory treatments. The research does not determine whether an individual will respond similarly, as findings describe group patterns, not personal outcomes.

Key Studies & References

  1. Meta-analysis of the efficacy and safety of naproxen sodium in the acute treatment of migraine
  2. Nonsteroidal anti-inflammatory drugs for primary dysmenorrhoea (Cochrane Review)
  3. Naproxen for Post-Operative Pain: A Comprehensive Review

Frequently Asked Questions (FAQ)

Common questions about Deproxen (FAQ)

Q: How quickly does Deproxen typically start to work?

According to official documents, the specific sodium salt formulation of Deproxen is designed to facilitate rapid and complete absorption in the body. This characteristic suggests the potential for a quicker onset of effect. However, regulatory information generally describes this process conceptually and does not specify a precise time frame (e.g., minutes or hours) for the effect to begin.

Q: Can Deproxen affect my mood or energy levels?

Official regulatory documents indicate that Deproxen may cause nervous system effects, such as dizziness and drowsiness, which could impact a person’s energy levels. There have also been less common reports of changes in mood, including depression. These are described as potential adverse reactions in the product labeling.

Q: Is it common for people to feel fatigued when starting Deproxen?

Official drug documents classify fatigue as an adverse reaction that occurs in the less common to uncommon categories. This means it is generally not listed among the most frequently reported side effects when using the medicine. Information on side effect frequency is based on what was observed in clinical studies.

Q: Are there any specific foods or drinks to avoid while using Deproxen?

Official labels note that alcohol may increase the risk of gastrointestinal bleeding while using Deproxen, and regulatory documents note that the use of alcohol is generally advised against. Additionally, substances like certain antacids may slow the rate at which the medicine is absorbed. The regulatory guidelines advise taking Deproxen with food or milk to help with stomach tolerance.

Q: Can I take over-the-counter pain relievers while using Deproxen?

Official documents describe that the use of Deproxen with other Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) is generally avoided due to a heightened risk of serious adverse effects. Non-NSAID pain relievers are not generally mentioned as presenting an interaction risk.

Q: Do older adults use a different form or strength of Deproxen?

Regulatory guidelines indicate that a reduced daily dosage should be considered for older adults. This is advised because official data shows an increased risk of serious adverse effects in this age group. The official documents do not mandate or recommend a different physical form (like a suspension instead of a tablet) for older adults.

Q: Are the side effects of Deproxen the same for everyone?

Official regulatory studies examine side effects by tracking patterns and probabilities across groups of patients, rather than predicting individual outcomes. Therefore, while common reactions are known, it is expected that not all patients will experience the same effects.

Q: Is Deproxen safe for people with high blood pressure?

Official documents state that Deproxen should be used with caution in patients with uncontrolled hypertension (high blood pressure). Regulatory information explains that the medicine may cause fluid retention and swelling, which can potentially worsen cardiovascular risk factors.

Q: What research has been done on the use of Deproxen in pediatric patients?

Research studies have been conducted to support the use of Deproxen for specific purposes in children aged two years and older. However, official regulatory documents state that the safety and effectiveness have not been established in children younger than two years of age.

Q: Will Deproxen make me sleepy or drowsy?

Official regulatory labels explicitly list drowsiness (also known as somnolence) as a reported adverse reaction. This reaction is categorized within the established frequency tiers in the official product information.

Q: Can women who are planning to become pregnant use Deproxen?

Official regulatory text advises that Deproxen is not recommended for women who are actively trying to conceive a child. This is due to documented effects on ovulation noted in some studies.

Q: Is it possible for Deproxen to lose effectiveness if stored improperly?

Regulatory requirements define specific storage conditions, such as temperature range and protection from light and moisture, which are necessary to maintain the product’s stability. If the medicine is not stored under these official conditions, changes to its stability may occur, which could potentially impact its effectiveness over time.

Q: Is Deproxen the name of the active ingredient, or is it a brand name?

Deproxen is described in official documents as a trade name used for the active ingredient. The active chemical ingredient in the medicine is called Naproxen Sodium.

Q: What happens if I stop taking Deproxen suddenly?

Regulatory labels for Deproxen do not list specific withdrawal symptoms associated with sudden discontinuation. As a Nonsteroidal Anti-Inflammatory Drug (NSAID), it is not classified as a narcotic or controlled substance, meaning it is not generally associated with physical dependence-related withdrawal effects.

Q: What should I do if I miss a Deproxen dose (general guidance)?

Official patient guidance typically advises taking the dose as soon as it is remembered, unless it is nearly time for the next scheduled dose. In that case, the guidelines advise to skip the missed dose and continue with the regular schedule.

Q: Does Deproxen cause weight gain or weight loss?

While significant weight changes are not commonly reported, official labels do list fluid retention (also known as edema) as a potential adverse reaction. Fluid retention is a physical change that may be related to changes in body weight.

Q: What is the risk of dependence or addiction with Deproxen?

Deproxen is classified as a Nonsteroidal Anti-Inflammatory Drug (NSAID). Since it is not classified as a controlled substance, regulatory information indicates that the risk of physical dependence or addiction is generally considered very low or negligible.

Q: Why does Deproxen have a warning about driving or operating machinery?

Regulatory information notes that certain adverse reactions, such as drowsiness, dizziness, or disturbances in vision, may occur with the medicine. Because these effects could potentially impair a person’s ability to operate machinery or drive safely, a warning is included in the labeling.

Q: Is there a generic version of Deproxen available?

The active ingredient in this medicine is Naproxen Sodium. Official drug compendia list this ingredient as being available under multiple generic names as well as various brand names.

Q: What is the difference between an allergic reaction and a common side effect of Deproxen?

Official documents define an allergic reaction as a severe hypersensitivity response, such as difficulty breathing or swelling, which is an absolute reason not to use the drug (contraindication). This is distinct from a common side effect, which is a more frequent, expected adverse reaction like headache or upset stomach.

Q: What kind of monitoring is needed while taking Deproxen (e.g., blood tests)?

Official labels state that patients receiving long-term treatment should be monitored for signs of renal (kidney) toxicity. This monitoring often includes regular checking of laboratory values such as serum creatinine and liver enzymes to assess organ function.

Q: Is it normal to have unusual dreams when taking Deproxen?

Official reports of nervous system effects associated with Deproxen include less common reports of sleep disturbances or unusual thought content. Although not specifically detailed as 'unusual dreams,' these general adverse reactions may encompass that experience.

Q: Can Deproxen affect blood sugar levels?

Official adverse event reporting includes less common reports of changes in glucose tolerance and hyperglycemia (high blood sugar). These reports indicate a possible but infrequent impact of the medicine on blood sugar levels.

Q: Is Deproxen considered a 'Black Box' warning drug?

Official documents released by the FDA include an explicit Boxed Warning for this medicine. This is a prominent warning that highlights the documented serious risks, such as cardiovascular thrombotic events and severe gastrointestinal adverse events.

Q: What is the elimination half-life of Deproxen, and what does that mean?

The official elimination half-life for Deproxen is described in pharmacokinetic studies as being approximately 12 to 17 hours. This term refers to the amount of time it takes for the concentration of the drug in the body to be reduced by one-half.

Q: Do I need a special prescription or form to get Deproxen?

The regulatory status of Deproxen varies by country and by strength. In some areas, lower doses are scheduled for over-the-counter (OTC) sale, while higher strengths of the medicine may be restricted to prescription-only status.

Q: How is Deproxen removed from the body?

The medicine is eliminated from the body primarily through the urine. It is removed mostly in the form of inactive compounds (metabolites) and conjugated drug. A small portion of the medicine is also eliminated through the feces.

Q: What happens if I accidentally take two doses of Deproxen?

Official guidance on acute overdosage mentions possible symptoms such as drowsiness, heartburn, or vomiting.

Q: Is it safe to use Deproxen while breastfeeding?

Regulatory documents state that Deproxen is excreted in human milk. Official guidance notes that a decision regarding continued use must be considered against the potential for serious adverse reactions in a nursing infant.

Q: What is the difference between Deproxen tablets and capsules?

Official documents list the available physical forms, such as the pressed tablet and the capsule (or caplet). Generally, capsules contain powder or liquid within a shell, which may lead to different absorption characteristics compared to a pressed tablet.

How should Deproxen be stored and disposed of?

How to Store and Dispose of Deproxen

Deproxen (Naproxen Sodium) must be stored at Controlled Room Temperature, specifically between 20 C and 25 C (68 F to 77 F). The regulatory requirements state the product must be protected from moisture and light, and storage must avoid excessive heat (above 40 C). To maintain stability, the medication should be kept in its original container with the lid tightly closed.

Handling and Safety

As with all medications, Deproxen must be stored out of reach of children.

Disposal

Unused or expired Deproxen should be disposed of in accordance with local regulations, often utilizing drug take-back programs. Pouring the medicine down a sink or toilet is generally discouraged by regulatory authorities.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Deproxen found in:

A-Z Index: